CoChat
Sign Up
Cited by 459Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Fates of CD8+ T cells in Tumor Microenvironment

Open access
Maimela, Nomathamsanqa Resegofetse, Liu, Shasha, Zhang, Yi·2019·Computational and Structural Biotechnology Journal
DOI 10.1016/j.csbj.2018.11.004PMC PMC6297055
Open this paper in CoChat — free accountOpen PDF

Abstract

Studies have reported a positive correlation between elevated CD8+ T cells in the tumor microenvironment (TME) and good prognosis in cancer. However, the mechanisms linking T cell tumor-infiltration and tumor rejection are yet to be fully understood. The cells and factors of the TME facilitate tumor development in various ways. CD8+ T cell function is influenced by a number of factors, including CD8+ T cell trafficking and localization into tumor sites; as well as CD8+ T cell growth and differentiation. This review highlights recent literature as well as currently evolving concepts regarding the fates of CD8+ T cells in the TME from three different aspects CD8+ T cell trafficking, differentiation and function. A thorough understanding of factors contributing to the fates of CD8+ T cells will allow researchers to develop new strategies and improve on already existing strategies to facilitate CD8+ T cell mediated anti-tumor function, impede T cell dysfunction and modulate the TME into a less immunosuppressive TME.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.csbj.2018.11.004

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The presence of tumor-infiltrating CD8+ T cells and the production of Th1 cytokines within tumors are correlated with favorable prognoses in overall survival and disease-free survival across various malignancies.

    “The presence of tumor-infiltrating CD8+ T cells and the production of Th1 cytokines within tumors have been correlated with favorable prognoses in terms of overall survival and disease-free survival across various malignancies [11,12,13,14].”

    From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [11]

    The Introduction links elevated cytotoxic CD8+ T cells in the tumor microenvironment with good prognosis in several cancer types. The section on co-stimulation describes Th1 cells and CD8+ T-cell function, but does not link intratumoral Th1 cytokine production to prognosis; the reviewed passages also do not establish both overall and disease-free survival outcomes. No page numbers are available in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 148

  1. [1]Nolz J.C. Molecular mechanisms of CD8+ T cell trafficking and localization Cell Mol Life Sci 72 2016 2461 2473 PMC4458431 25577280
  2. [2]Kim P.S. Ahmed R. Features of responding T cells in cancer and chronic infection Curr Opin Immunol 22 2010 223 230 20207527 PMC2892208
  3. [3]Kmiecik J. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level J Neuroimmunol 264 2013 71 83 24045166
  4. [4]Piersma S.J. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer Cancer Res 67 2007 354 361 17210718
  5. [5]Bellone M. Calcinotto A. Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes Front Oncol 3 2013 1 15 24062984 PMC3769630
  6. [6]Chung A. Lee J. Ferrera N. Targeting the tumour vasculature: insights from physiological angiogenesis Nat Rev Cancer 10 2010 505 514 20574450
  7. [7]Oelkrug C. Ramage J.M. Enhancement of T cell recruitment and infiltration into tumours Clin Exp Immunol 178 2014 1 8 PMC4360188 24828133
  8. [8]Harty J.T. Badovinac V.P. Shaping and reshaping CD8+ T-cell memory Nat Rev Immunol 8 2008 107 119 18219309
  9. [9]Butler N.S. Nolz J.C. Harty J.T. Immunologic considerations for generating memory CD8 T cells through vaccination Cell Microbiol 13 2011 925 933 21501363 PMC3116979
  10. [12]Slaney C.Y. Kershaw M.H. Darcy P.K. Trafficking of T cells into tumors Cancer Res 74 2014 7168 7175 25477332
  11. [14]Mellor A.L. Munn D.H. Creating immune privilege: active local suppression that benefits friends, but protects foes Nat Rev Immunol 8 2008 74 80 18064049
  12. [15]Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth Oncogene 27 2008 5904 5912 18836471 PMC3689267
  13. [16]Mbeunkui L. Johann D.J. Cancer and the tumor microenvironment: a review of an essential relationship Cancer Chemother Pharmacol 63 2009 571 582 19083000 PMC2858592
  14. [17]Becker C. Hald M. Immune-suppressive properties of the tumor microenvironment Cancer Immunol Immunother 62 2013 1137 1148 23666510 PMC11029603
  15. [19]Zhou L. Yang K. Wickett R.R. Zhang Y. Dermal fibroblasts induce cell cycle arrest and block epithelial–mesenchymal transition to inhibit the early stage melanoma development Cancer Med 5 2016 1566 1579 27061029 PMC4944884
  16. [20]Qiao Y. IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma Oncogene 37 2018 873 883 29059160
  17. [21]Wang F. CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion Cancer Immunol Immunother 64 2015 965 976 25944005 PMC11028729
  18. [22]Yang L. Zhang Y. Tumor-associated macrophages, potential targets for cancer treatment Biomark Res 5 2017 1 6 28804638 PMC5549387
  19. [23]Martinez F.O. Sica A. Mantovani A. Locati M. Macrophage activation and polarization Front Biosci 13 2008 453 461 17981560
  20. [24]Filipazzi P. Huber V. Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients Cancer Immunol Immunother 61 2012 255 263 22120756 PMC11029611
  21. [25]Chandra D. Gravekamp C. Myeloid-derived suppressor cells Cellular missiles to target tumors Oncoimunology 2 2014 e26967 PMC3890360 24427545
  22. [26]Brandau S. Moses K. Lang S. The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins? Semin Cancer Biol 23 2013 171 182 23459190
  23. [27]Hanson E.M. Clements V.K. Sinha P. Ilkovitch D. Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate L-Selectin expression on CD4+ and CD8+ t cells J Immunol 183 2009 937 944 19553533 PMC2800824
  24. [28]Steding C.E. The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis Immunology 133 2011 221 238 21453419 PMC3088984
  25. [29]Molon B. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells J Exp Med 208 2011 1949 1962 21930770 PMC3182051
  26. [30]Bruger A.M. How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions Cancer Immunol Immunother 2018 PMC11028070 29785656
  27. [31]Zou W. Regulatory T cells, tumour immunity and immunotherapy Nat Rev Immunol 6 2006 295 308 16557261
  28. [32]Ghiringhelli F. CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner J Exp Med 202 2005 1075 1085 16230475 PMC2213209
  29. [33]Curiel T.J. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 2004 942 949 15322536
  30. [34]Andersen M.H. Schrama D. Thor Straten P. Becker J.C. Cytotoxic T Cells J Invest Dermatol 126 2006 32 41 16417215
  31. [35]McClory S. Evidence for a step-wise program of T cell development within the human tonsil J Clin Invest 122 2012 1403 1415 22378041 PMC3314444
  32. [36]Wongtrakoongate P. Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries World J Stem Cells 7 2015 137 148 25621113 PMC4300924
  33. [37]Anderson K.G. Stromnes I.M. Greenberg P.D. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies Cancer Cell 31 2017 311 325 28292435 PMC5423788
  34. [38]Merelli B. Massi D. Cattaneo L. Mandalà M. Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities Crit Rev Oncol Hematol 89 2014 140 165 24029602
  35. [40]Shi L. Adenosine signaling: next checkpoint for gastric cancer immunotherapy? Int Immunopharmacol 63 2018 58 65 30075429
  36. [41]Gholami M.D. Exhaustion of T lymphocytes in the tumor microenvironment: significance and effective mechanism Cell Immunol 322 2017 1 14 29079339
  37. [42]Brand A. LDHA-Associated lactic acid production blunts tumor immunosurveillance by T and NK cells Cell Metab 24 2016 657 671 27641098
  38. [43]Hodge G. Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells Clin Exp Immuology 178 2014 79 85 PMC4360197 24894428
  39. [44]Permanyer M. Bosnjak B. Forster R. Dendritic cells, T cells and lymphatics: dialogues in migration and beyond Curr Opin Immunol 53 2018 173 179 29857205
  40. [45]Randolph G.J. Ivanov S. Zinselmeyer B.H. Scallan J.P. The lymphatic system: Integral roles in immunity Annu Rev Immunol 35 2017 31 52 27860528 PMC5551392
  41. [46]James K.D. Jenkinson W.E. Anderson G. T-cell egress from the thymus: should I stay or should I go? J Leukoc Biol 104 2017 275 284 PMC6174998 29485734
  42. [47]Bandola-Simon J. Roche P.A. Dysfunction of antigen processing and presentation by dendritic cells in cancer Mol Immunol 2018 PMC6173666 29628265
  43. [49]De La Cruz-Merino L. Immune microenvironment in colorectal cancer: a new hallmark to change old paradigms Clin Dev Immunol 2011 2011 2011 PMC3226426 22162710
  44. [51]Masopust D. Schenkel J.M. The integration of T cell migration, differentiation and function Nat Rev Immunol 13 2013 309 320 23598650
  45. [52]Harlin H. Chemokine expression in melnma metastasiswith CD8+ T-cell recruitment Cancer Res 69 2009 1 18 19293190 PMC3886718
  46. [53]Mulligan A.M. Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry Clin Cancer Res 19 2013 336 346 23213058 PMC3548938
  47. [54]Liu J. Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma Oncotarget 6 2015 24978 26489 26317795 PMC4694808
  48. [55]Matsumura S. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells J Immunol 181 2008 3099 3107 18713980 PMC2587101
  49. [56]Laufer J.M. Legler D.F. Beyond migration — Chemokines in lymphocyte priming, differentiation, and modulating effector functions J Leukoc Biol 1 2018 1 12 29668063
  50. [57]Ferretti E. Pistoia V. Corcione A. Role of fractalkine/ CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies Mediators Inflamm 2014 480941 2014 PMC3985314 24799766
  51. [58]Siddiqui I. Erreni M. Van Brakel M. Debets R. Allavena P. Enhanced recruitment of genetically modified CX3CR1-positive human T cells into fractalkine/CX3CL1 expressing tumors: Importance of the chemokine gradient J Immunother Cancer 4 2016 1 12 PMC4836203 27096098
  52. [59]Garris C.S. Blaho V.A. Hla T. Han M.H. Sphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyond Immunology 142 2014 347 353 24597601 PMC4080950
  53. [60]Nolz J.C. Starbeck-Miller G.R. Harty J.T. Naive, effector and memory CD8 T cell trafficking: parallels and distinctions Immunotherapy 3 2011 1223 1233 21995573 PMC3214994
  54. [61]Paulsen M. Janssen O. Pro- and anti-apoptotic CD95 signalling in T cells Cell Commun Signal 9 2011 PMC3090738 21477291
  55. [62]Hanahan D. Weinberg R.A. The hallmarks of cancer Cell 100 2000 57 70 10647931
  56. [63]Kinter A.L. The common y- chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands J Immunol 181 2008 6738 6746 18981091
  57. [64]Huang A. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies Nat Sci Rep 7 2017 1 9 PMC5311961 28202921
  58. [65]Jiang Y. Li Y. Zhu B. T-cell exhaustion in the tumor microenvironment Cell Death Dis 6 2015 1 9 PMC4669840 26086965
  59. [66]Finn O. Immuno-Oncology J. Understanding the function and dysfunction of the immune system in cancer Ann Oncol 23 2012 86 89 22918931 PMC4085883
  60. [67]Obst R. The timing of T cell priming and cycling Front Immunol 6 2015 1 10 26594213 PMC4633513
  61. [68]González-Amaro R. Cortés J.R. Sánchez-Madrid F. Martín P. Is CD69 an effective brake to control inflammatory diseases? Trends Mol Med 19 2013 625 632 23954168 PMC4171681
  62. [69]Liu J.Y. CTL- vs T reg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma Br J Cancer 113 2015 747 755 26284335 PMC4559838
  63. [70]Linch S.N. McNamara M.J. Redmond W.L. OX40 agonists and combination immunotherapy: putting the pedal to the metal Front Oncol 5 2015 1 14 25763356 PMC4329814
  64. [71]Lei F. Regulation of A1 by OX40 contributes to CD8+T cell survival and anti-tumor activity PLoS One 8 2013 257 264 PMC3731243 23936461
  65. [72]Crepeau R.M. Ford M.L. Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity Expert Opin Biol Ther 17 2017 1001 1012 28525959 PMC5590720
  66. [73]Chen L. Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future J Clin Invest 125 2015 3384 3391 26325035 PMC4588282
  67. [74]Shin D. Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next Curr Opin Immunol 33 2015 23 35 25621841
  68. [75]Zou W. Wolchok J. Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations Sci Transl Med 2016 PMC4859220 26936508
  69. [76]Kamphorst A.O. Ahmed R. Manipulating the PD-1 pathway to improve immunity Curr Opin Immunol 25 2013 381±8 PMC5946314 23582509
  70. [77]Ma W. Gilligan B.M. Yuan J. Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy J Hematol Oncol 9 2016 47 27234522 PMC4884396
  71. [78]Maj T. Wei S. Welling T. Zou W. T cells and costimulation in cancer Cancer J 19 2013 473 482 24270346
  72. [79]Faget J. ICOS ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells Cancer Res 72 2012 6130 6141 23026134
  73. [80]Zhu J. Yamane H. Paul W.E. Differentiation of effector CD4 T cell populations Annu Rev Immunol 28 2010 445 489 20192806 PMC3502616
  74. [81]Martin-Orozco N. Th17 cells promote cytotoxic T cell activation in tumor immunity Immunity 31 2009 787 798 19879162 PMC2787786
  75. [82]Gollmer K. CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway Blood 114 2009 580 588 19451552 PMC2713469
  76. [83]Ito T. Plasmacytoid dendritic cells prime IL-10–producing T regulatory cells by inducible costimulator ligand J Exp Med 204 2007 105 115 17200410 PMC2118437
  77. [84]Riella L.V. Murakami N. Co-inhibitory pathways and their importance in immune regulation Transplantation 98 2014 3 14 24978034
  78. [86]Fan J. Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia Mol Syst Biol 9 2013 1 11 PMC3882799 24301801
  79. [87]Mocellin S. Bronte V. Nitti D. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities Med Res Rev 27 2007 317 352 16991100
  80. [88]O'Flanagan C.H. Bowers L.W. Hursting S.D. A weighty problem: Metabolic perturbations and the obesity-cancer link Horm Mol Biol Clin Invest 23 2015 47 57 PMC4839982 26167982
  81. [89]Nieman K.M. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth Nat Med 17 2011 1498 1503 22037646 PMC4157349
  82. [90]Kouidhi S. Elgaaied A.B. Chouaib S. Impact of metabolism on T-cell differentiation and function and cross talk with tumor microenvironment Front Immunol 8 2017 1 13 28348562 PMC5346542
  83. [91]Clayton A. Al-Taei S. Webber J. Mason M.D. Tabi Z. Cancer eosomes express CD39 and CD73, which suppress T cells through adenosine production J Immunol 187 2011 676 683 21677139
  84. [92]Deaglio S. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression J Exp Med 204 2007 1257 1265 17502665 PMC2118603
  85. [94]Warburg B.Y.O. Wind F. The metabolism of tumors in the Body J Gen Physiol 8 1926 519 530 PMC2140820 19872213
  86. [95]Cohen R. Targeting cancer cell metabolism in pancreatic adenocarcinoma Oncotarget 6 2015 16832 16847 26164081 PMC4627277
  87. [96]Beckermann K.E. Dudzinski S.O. Rathmell J.C. Dysfunctional T cell metabolism in the tumor microenvironment Cytokine Growth Factor Rev 35 2017 7 14 28456467 PMC5710836
  88. [97]Kim H. Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment Mol Ther 16 2008 599 606 18227840
  89. [99]Song M. Chen X. Wang L. Zhang Y. Future of anti-PD-1 / PD-L1 applications: Combinations with other therapeutic regimens Chin J Cancer Res 4 2018 157 172 PMC5953954 29861603
  90. [100]Xu Y. Glycolysis determines dichotomous regulation of T cell subsets in hypoxia J Clin Invest 126 2016 2678 2688 27294526 PMC4922684
  91. [101]Caldwell C.C. Differential Effects of Physiologically Relevant Hypoxic Conditions on T Lymphocyte Development and Effector Functions J Immunol 167 2001 6140 6149 11714773
  92. [102]Cho H. Lee Y.S. Kim J. Chung J.Y. Kim J.H. Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer Cancer Invest 31 2013 607 615 24164300
  93. [103]Krzeslak A. Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers Pathol Oncol Res 18 2012 721 728 22270867 PMC3342495
  94. [104]Siska P.J. Rathmell J.C. T cell metabolic fitness in antitumor immunity Trends Immunol 36 2015 1 8 25773310 PMC4393792
  95. [105]Rodriguez P.C. Ochoa A.C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives Immunol Rev 222 2008 180 191 18364002 PMC3546504
  96. [106]Ottensmeier C.H. Upregulated glucose metabolism correlates inversely with CD8+ T-cell infiltration and survival in squamous cell carcinoma Cancer Res 76 2016 4136 4148 27206847
  97. [107]Davis-Yadley A.H. Abbott A.M. Pimiento J.M. Chen D.T. Malafa M.P. Increased expression of the glucose transporter type 1 gene is associated with worse overall survival in resected pancreatic adenocarcinoma Pancreas 45 2016 974 979 26692443 PMC4912950
  98. [108]Zhang Y. Enhancing CD8 + T cell fatty acid catabolism within a metabolically challenging tumor microenvironment icreases the efficacy of melanoma immunotherapy Cancer Cell 32 2017 377 391 28898698 PMC5751418
  99. [109]Lu K. Expression and clinical significance of glucose transporter-1 in pancreatic cancer Oncol Lett 12 2016 243 249 27347132 PMC4906709
  100. [110]Gordon-Alonso M. Hirsch T. Wildmann C. van der Bruggen P. Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration Nat Commun 8 2017 1 15 28986561 PMC5630615
  101. [111]Gordon-Alonso M. Demotte N. van der Bruggen P. Sugars boost exhausted tumor- infiltrating lymphocytes by counteracting immunosuppressive activities of galectins Oncoimmunology 3 2014 2 4 PMC4091051 25097806
  102. [112]Markowska A.I. Jefferies K.C. Panjwani N. Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells J Biol Chem 286 2011 29913 29921 21715322 PMC3191032
  103. [113]Demotte N. A Galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice Cancer Res 70 2010 7476 7489 20719885
  104. [114]Kouo T. Galectin-3 shapes antitumor immune responses by suppressing CD8 + T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells Cancer Immunonolgy Res 3 2015 412 423 PMC4390508 25691328
  105. [115]Henning A.N. Roychoudhuri R. Restifo N.P. Epigenetic control of CD8+ T cell differentiation Nat Rev Immunol 2018 PMC6327307 29379213
  106. [116]Pathania R. DNMT1 is essential for mammary and cancer stem cell maintenance and tumorigenesis Nat Commun 6 2015 706 721 PMC4410389 25908435
  107. [119]Zhang Z. Structural basis for DNMT3A-mediated de novo DNA methylation Nature 554 2018 387 391 29414941 PMC5814352
  108. [120]Youngblood B. Effector CD8 T cells dedifferentiate into long-lived memory cells Nature 552 2018 404 409 PMC5965677 29236683
  109. [121]Gray S.M. Kaech S.M. Staron M.M. The interface between transcriptional and epigenetic control of effector and memory CD8+ T-cell differentiation Immunol Rev 261 2014 157 168 25123283 PMC4267690
  110. [122]Kasler H.G. Histone deacetylase 7 regulates cell survival and TCR signaling in CD4/CD8 double-positive thymocytes J Immunol 186 2011 4782 4793 21398603
  111. [123]McLane L. Different localizations of T-bet and Eomes in CD8 T-cell memory populations J Immunol 190 2013 3207 3215 23455505 PMC3608800
  112. [124]Li G. T-Bet and Eomes regulate the balance between the effector/central memory T cells versus memory stem like T cells PLoS One 8 2013 1 10 PMC3694876 23826287
  113. [125]Nayar R. IRF4 regulates the ratio of T-Bet to eomesodermin in CD8+T cells responding to persistent LCMV infection PLoS One 10 2015 1 20 PMC4699851 26714260
  114. [126]Zhu L. Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia J Hematol Oncol 10 2017 1 13 28629373 PMC5477125
  115. [127]Braun J. Frentsch M. Thiel A. Hobit and human effector T-cell differentiation: the beginning of a long journey Eur J Immunol 45 2015 2762 2765 26440905
  116. [128]Amsen D. van Gisbergen K.P.J.M. Hombrink P. van Lier R.A.W. Tissue-resident memory T cells at the center of immunity to solid tumors Nat Immunol 19 2018 538 546 29777219
  117. [129]Rao R.R. Li Q. Bupp M.R.G. Shrikant P.A. Transcription factor Foxo1 represses T-bet mediated effector functions and promotes memory CD8+ T cell differentiation Immunity 36 2012 374 387 22425248 PMC3314246
  118. [130]Coma S. Id2 promotes tumor cell migration and invasion through transcriptional repression of semaphorin 3F Cancer Res 70 2011 3823 3832 PMC2862101 20388805
  119. [131]Chen S. Zhang Y. Kuzel T.M. Zhang B. Regulating tumor myeloid-derived suppressor cells by microRNAs Cancer cell Microenviron 2 2015 1 6 PMC4440580 26005707
  120. [132]Yang C.Y. The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8 + T cell subsets Nat Immunol 12 2011 1221 1230 22057289 PMC3872000
  121. [134]Xu Y. Higher numbers of T-Bet + tumor- infiltrating lymphocytes associate with better survival in human epithelial ovarian cancer Cell Physiol Biochem 41 2017 475 483 28214872 PMC9393827
  122. [135]Trifari S. MicroRNA-directed program of cytotoxic CD8+ T-cell differentiation Proc Natl Acad Sci U S A 110 2013 18608 18613 24163352 PMC3831973
  123. [136]Smith N.L. Wissink E.M. Grimson A. Rudd B.D. miR-150 regulates differentiation and cytolytic effector function in CD8 + T cells Sci Rep 5 2015 1 11 PMC4637875 26549197
  124. [137]Chen Z. miR-150 regulates memory CD8 T cell differentiation via c-Myb Cell Rep 20 2017 2584 2597 28903040 PMC5611819
  125. [138]Shin H.M. Epigenetic modifications induced by blimp-1 regulate CD8+ T cell memory progression during acute virus infection Immunity 39 2013 661 675 24120360 PMC3808842
  126. [139]Khan A.A. Penny L.A. Yuzefpolskiy Y. Sarkar S. Kalia V. MicroRNA-17~92 regulates effector and memory CD8 T-cell fates by modulating proliferation in response to infections Blood 121 2013 4473 4483 23596046
  127. [140]Dudda J.C. MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer Immunity 38 2013 742 753 23601686 PMC3788592
  128. [141]Ji Y. Hocker J.D. Gattinoni L. Enhancing adoptive T cell immunotherapy with microRNA therapeutics Semin Immunol 28 2016 45 53 26710685 PMC4862908
  129. [142]Porta C. Paglino C. Mosca A. Targetting PI3K/Akt/Mtor signalling in cancer Front Oncol 4 2014 e64 PMC3995050 24782981
  130. [143]Murray I.A. Patterson A.D. Perdew G.H. Aryl hydrocarbon receptor ligands in cancer: friend and foe Nat Rev Cancer 14 2014 801 814 25568920 PMC4401080
  131. [144]Zeng H. Chi H. mTOR signaling in the differentiation and function of regulatory and effector T cells Curr Opin Immunol 46 2017 103 111 28535458 PMC5554750
  132. [145]Eil R. Ionic immune suppression within the tumour microenvironment limits T cell effector function Nat Publ Gr 537 2016 539 543 PMC5204372 27626381
  133. [146]Gattinoni L. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells Nat Med 15 2009 808 813 19525962 PMC2707501
  134. [147]Gattinoni L. Klebanoff C.A. Restifo N.P. Paths to stemness: building the ultimate antitumour T cell Nat Rev Cancer 12 2012 671 684 22996603 PMC6352980
  135. [148]Pai S.G. Wnt/ beta-catenin pathway: modulating anticancer immune response J Hematol Oncol 10 2017 1 12 28476164 PMC5420131
  136. [149]Backer R.A. A central role for notch in effector CD8+ T cell differentiation Nat Immunol 15 2014 1143 1151 25344724 PMC4232996
  137. [150]Wells A.C. Modulation of let-7 miRNAs controls the differentiation of effector CD8 T cells Elife 6 2017 1 22 PMC5550279 28737488
  138. [151]Kondo T. Notch-mediated conversion of activated T cells into stem cell memory-like T cells for adoptive immunotherapy Nat Commun 8 2017 1 14 28530241 PMC5458121
  139. [152]Tsukumo S. Yasutomo K. Osborne B.A. Regulation of CD8+ T cells and antitumor immunity by notch signaling Front Immunol 9 2018 1 7 29441071 PMC5797591
  140. [154]Bartel D. Micrornas P. Target recognition and regulatory functions Cell 136 2009 215 233 19167326 PMC3794896
  141. [155]Cho O.H. Notch regulates cytolytic effector function in CD8+ T cells J Immunol 182 2015 3380 3389 PMC4374745 19265115
  142. [156]Fuchs C.S. Safety and efficacy of Pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer Phase 2 clinical KEYNOTE-059 Trial JAMA Oncol 06510 2018 1 8 PMC5885175 29543932
  143. [158]Haymaker C.L. Metastatic melanoma patient had a complete response with clonal expansion after whole brain radiation and PD-1 blockade Cancer Immunol Res 5 2017 100 106 28062513 PMC7055516
  144. [159]Kamphorst A.O. Rescue of exhausted CD8 T cells by PD-1 targeted therapies is CD28-dependent Science 355 2017 1423 1427 (80-.) 28280249 PMC5595217
  145. [160]Golubovskaya V. Wu L. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy Cancers (Basel) 8 2016 E36 PMC4810120 26999211
  146. [161]Lu Y. Robbins P.F. Seminars in Immunology Cancer immunotherapy targeting neoantigens Semin Immunol 28 2016 22 27 26653770 PMC4862880
  147. [162]Zou W. Wolchok J.D. Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers and combinations Sci Transl Med 8 2016 328rv4 PMC4859220 26936508
  148. [164]Nouri-Shirazi M. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses J Immunol 165 2000 3797 3803 11034385

Cited by

Sorted by citations

Authors
Maimela, N. R., Liu, S., & Zhang, Y.
Affiliations
First Affiliated Hospital of Zhengzhou University (CN)
Corresponding author
Zhang, Yi
ORCID
Venue
Computational and Structural Biotechnology Journal
Publisher
American Association for the Advancement of Science (AAAS)
Published
2018-12-13
Volume
17
Pages
1-13
ISSN
2001-0370 (ISSN-L)
DOI
10.1016/j.csbj.2018.11.004
PMC
PMC6297055
OpenAlex
W2901513648
Cited by
459
References
14
Citations by year
2026: 22 · 2025: 48 · 2024: 69 · 2023: 76 · 2022: 78 · 2021: 85 · 2020: 65 · 2019: 13
FWCI
4.25
Type
journal article
Language
en
Open access
Licence
Locations
  • Computational and Structural Biotechnology Journal (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81771781)
  • National Basic Research Program of China (2016YFC1303501)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
CD8+ T cells, tumor microenvironment, T cell migration, T cell differentiation, T cell function, tumor-infiltrating lymphocytes, antitumor immunity, immunosuppression, T cell dysfunction, cancer immunotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review